Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4115-4126

  Nguyen, Jack T ^a   Hoopes, Justin D ^b   Smee, Donald F ^b   Prichard, Mark N ^c   Driebe, Elizabeth M ^d   Engelthaler, David M ^d   Le, Minh H ^a   Keim, Paul S ^d   Spence, R Paul ^a   Went, Gregory T ^a  

^a Adamas Pharmaceuticals Inc   (United States)

^b UTAH STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR; RIBAVIRIN;

ARTICLE; AVIAN INFLUENZA; CELL STRAIN; CONCENTRATION RESPONSE; CYTOPATHOGENIC EFFECT; DRUG ANTAGONISM; DRUG POTENTIATION; IN VITRO STUDY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIRUS STRAIN; WILD TYPE;

AMANTADINE; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; DRUG SYNERGISM; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; ORTHOMYXOVIRIDAE; OSELTAMIVIR; POLYMERASE CHAIN REACTION; RIBAVIRIN;

EID: 70349331605     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00476-09     Document Type: Article

References (51)

1. Abdel-Ghafar, A. N., T. Chotpitayasunondh, Z. Gao, F. G. Hayden, D. H. Nguyen, M. D. de Jong, A. Naghdaliyev, J. S. Peiris, N. Shindo, S. Soeroso, and T. M. Uyeki. 2008. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358:261-273.
2. Belshe, R. B., M. H. Smith, C. B. Hall, R. Betts, and A. J. Hay. 1988. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62:1508-1512. (Pubitemid 18133166)
3. Bright, R. A., M. J. Medina, X. Xu, G. Perez-Oronoz, T. R. Wallis, X. M. Davis, L. Povinelli, N. J. Cox, and A. I. Klimov. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366:1175-1181.
4. Browne, M. J. 1979. Mechanism and specificity of action of ribavirin. Antimicrob. Agents Chemother. 15:747-753.
5. Cameron, C. E., and C. Castro. 2001. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr. Opin. Infect. Dis. 14:757-764.
6. CDC. 2009. FluView: 2008-2009 influenza season week 53, ending January 3, 2009. http://www.cdc.gov/flu/weekly.
7. Coen, D. M. 1991. The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antivir. Res. 15:287-300.
8. Covington, E., D. B. Mendel, P. Escarpe, C. Y. Tai, K. Soderbarg, and N. A. Roberts. 1999. Phenotypic and genotypic assay of influenza neuraminidase indicates a low incidence of viral drug resistance during treatment with oseltamivir. Proceedings of the Second International Symposium on Influenza and other Respiratory Viruses, Grand Cayman, Cayman Islands.
9. Crotty, S., D. Maag, J. J. Arnold, W. Zhong, J. Y. Lau, Z. Hong, R. Andino, and C. E. Cameron. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:1375-1379.
10. de Jong, M. D., C. P. Simmons, T. T. Thanh, V. M. Hien, G. J. Smith, T. N. Chau, D. M. Hoang, N. V. Chau, T. H. Khanh, V. C. Dong, P. T. Qui, B. V. Cam, Q. Ha do, Y. Guan, J. S. Peiris, N. T. Chinh, T. T. Hien, and J. Farrar. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12:1203-1207.
11. de Jong, M. D., T. T. Tran, H. K. Truong, M. H. Vo, G. J. Smith, V. C. Nguyen, V. C. Bach, T. Q. Phan, Q. H. Do, Y. Guan, J. S. Peiris, T. H. Tran, and J. Farrar. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672.
12. Deyde, V. M., X. Xu, R. A. Bright, M. Shaw, C. B. Smith, Y. Zhang, Y. Shu, L. V. Gubareva, N. J. Cox, and A. I. Klimov. 2007. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196:249-257.
13. Galabov, A. S., L. Simeonova, and G. Gegova. 2006. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antivir. Chem. Chemother. 17:251-258.
14. Govorkova, E. A., H. B. Fang, M. Tan, and R. G. Webster. 2004. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic antiinfluenza virus effects in MDCK cells. Antimicrob. Agents Chemother. 48: 4855-4863.
15. Gubareva, L. V., L. Kaiser, and F. G. Hayden. 2000. Influenza virus neuraminidase inhibitors. Lancet 355:827-835.
16. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. Mc- Mahon, L. Jonas, A. Meibohm, D. Holder, W. A. Schleif, J. H. Condra, E. A. Emini, R. Isaacs, J. A. Chodakewitz, and D. D. Richman. 1998. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 280:35-41.
17. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. Mc- Mahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
18. Hay, A. J., A. J. Wolstenholme, J. J. Skehel, and M. H. Smith. 1985. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 4:3021-3024.
19. Hayden, F. G. 1986. Combinations of antiviral agents for treatment of influenza virus infections. J. Antimicrob. Chemother. 18(Suppl. B):177-183.
20. Hayden, F. G., R. G. Douglas, Jr., and R. Simons. 1980. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob. Agents Chemother. 18:536-541.
21. Hayden, F. G., and A. J. Hay. 1992. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol. 176:119-130.
22. Hayden, F. G., A. D. Osterhaus, J. J. Treanor, D. M. Fleming, F. Y. Aoki, K. G. Nicholson, A. M. Bohnen, H. M. Hirst, O. Keene, and K. Wightman. 1997. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N. Engl. J. Med. 337:874-880.
23. Ilyushina, N. A., N. V. Bovin, R. G. Webster, and E. A. Govorkova. 2006. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antivir. Res. 70:121-131.
24. Ilyushina, N. A., A. Hay, N. Yilmaz, A. C. Boon, R. G. Webster, and E. A. Govorkova. 2008. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 52:3889-3897.
25. Ilyushina, N. A., E. Hoffmann, R. Salomon, R. G. Webster, and E. A. Govorkova. 2007. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther. 12:363-370.
26. Ison, M. G., L. V. Gubareva, R. L. Atmar, J. Treanor, and F. G. Hayden. 2006. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193:760-764.
27. Jefferson, T., V. Demicheli, C. Di Pietrantonj, and D. Rivetti. 2006. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst. Rev. 2006:CD001169.
28. Kandun, I. N., E. Tresnaningsih, W. H. Purba, V. Lee, G. Samaan, S. Harun, E. Soni, C. Septiawati, T. Setiawati, E. Sariwati, and T. Wandra. 2008. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 372:744-749.
29. Kiso, M., K. Mitamura, Y. Sakai-Tagawa, K. Shiraishi, C. Kawakami, K. Kimura, F. G. Hayden, N. Sugaya, and Y. Kawaoka. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765. (Pubitemid 39165094)
30. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
31. Leneva, I. A., N. Roberts, E. A. Govorkova, O. G. Goloubeva, and R. G. Webster. 2000. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antivir. Res. 48:101-115.
32. Madren, L. K., C. J. Shipmen, and F. G. Hayden. 1995. In vitro inhibitory effects of combinations of anti-influenza agents. Antivir. Chem. Chemother. 6:109-113.
33. Mendel, D. B., C. Y. Tai, P. A. Escarpe, W. Li, R. W. Sidwell, J. H. Huffman, C. Sweet, K. J. Jakeman, J. Merson, S. A. Lacy, W. Lew, M. A. Williams, L. Zhang, M. S. Chen, N. Bischofberger, and C. U. Kim. 1998. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42:640-646.
34. Molinari, N. A., I. R. Ortega-Sanchez, M. L. Messonnier, W. W. Thompson, P. M. Wortley, E. Weintraub, and C. B. Bridges. 2007. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25:5086-5096.
35. Monto, A. S., J. L. McKimm-Breschkin, C. Macken, A. W. Hampson, A. Hay, A. Klimov, M. Tashiro, R. G. Webster, M. Aymard, F. G. Hayden, and M. Zambon. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50:2395-2402.
36. Morrison, D., S. Roy, C. Rayner, A. Amer, D. Howard, J. R. Smith, and T. G. Evans. 2007. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS ONE 2:e1305.
37. Nicholson, K. G., F. Y. Aoki, A. D. Osterhaus, S. Trottier, O. Carewicz, C. H. Mercier, A. Rode, N. Kinnersley, P. Ward, et al. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355:1845-1850. (Pubitemid 30311875)
38. Prichard, M. N., L. E. Prichard, and C. Shipman, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
39. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-205.
40. Raboud, J. M., J. S. Montaner, B. Conway, S. Rae, P. Reiss, S. Vella, D. Cooper, J. Lange, M. Harris, M. A. Wainberg, P. Robinson, M. Myers, and D. Hall. 1998. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 12:1619-1624.
41. Reed, L. J., and M. Muench. 1938. A simple method of estimating fifty percent end points. Am. J. Hyg. 27:493-498.
42. Sasadeusz, J. J., S. L. Locarnini, and G. Macdonald. 2007. Why do we not yet have combination chemotherapy for chronic hepatitis B? Med. J. Aust. 186:204-206.
43. Sheu, T. G., V. M. Deyde, M. Okomo-Adhiambo, R. J. Garten, X. Xu, R. A. Bright, E. N. Butler, T. R. Wallis, A. I. Klimov, and L. V. Gubareva. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52:3284-3292.
44. Smee, D. F., K. W. Bailey, A. C. Morrison, and R. W. Sidwell. 2002. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 48:88-93.
45. Smee, D. F., J. H. Huffman, A. C. Morrison, D. L. Barnard, and R. W. Sidwell. 2001. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob. Agents Chemother. 45:743-748.
46. Smee, D. F., B. L. Hurst, M. H. Wong, K. W. Bailey, and J. D. Morrey. 2009. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother.
47. Smee, D. F., M. H. Wong, K. W. Bailey, and R. W. Sidwell. 2006. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir. Chem. Chemother. 17:185-192.
48. Soriano, V., A. Madejon, E. Vispo, P. Labarga, J. Garcia-Samaniego, L. Martin-Carbonero, J. Sheldon, M. Bottecchia, P. Tuma, and P. Barreiro. 2008. Emerging drugs for hepatitis C. Expert Opin. Emerg. Drugs. 13:1-19.
49. van der Vries, E., B. van den Berg, and M. Schutten. 2008. Fatal oseltamivir-resistant influenza virus infection. N. Engl. J. Med. 359:1074-1076.
50. Ward, C. L., M. H. Dempsey, C. J. Ring, R. E. Kempson, L. Zhang, D. Gor, B. W. Snowden, and M. Tisdale. 2004. Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement. J. Clin. Virol. 29:179-188.
51. WHO. 13 June 2008. Influenza A(H1N1) virus resistance to oseltamivir - last quarter 2007 to first quarter 2008. http://www.who.int/csr/disease/ influenza/oseltamivir-summary/en/print.html.